The 2026 American Association for Cancer Research (AACR) Annual Meeting will be held April 17–22 at the San Diego Convention Center in San Diego, California. Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) will present the latest findings from two preclinical programs at the meeting. These two programs respectively showcase the Company’s innovative efforts in two frontier areas: T cell engager drug conjugates (TDCs) and bispecific ADCs, further validating the Company’s R&D strategy centered on the synergy and integration of its three core technology platforms: LeadsBody (CD3 T-Cell Engager Platform), X-body (4-1BB Engager Platform), and TOPiKinectics (ADC Technology Platform).

LBL-054 TDC: A first-in-class CDH17 targeted T cell engager drug conjugate

LBL-054 TDC is a first-in-class T cell engager drug conjugate targeting CDH17 and CD3. It was developed using Leads Biolabs’ proprietary antibody platform and conjugated with the TOPiKinetics linker-payload platform. By merging the dual mechanisms of TCE and ADC, it enables precise treatment of gastrointestinal cancers—including colorectal, gastric, and pancreatic cancer—with high efficacy and low toxicity.

Preclinical studies show that LBL-054 TDC combines the potent direct killing effect of an ADC with the T-cell redirecting and activation activity of a TCE both in vitro and in vivo. It exhibits strong binding and internalization on tumor cells with potent cytotoxicity, while showing weak binding, no internalization, and no cytotoxicity on T cells. In T cell-dependent cellular cytotoxicity (TDCC) assays, LBL-054 TDC induced potent cytotoxicity across varying effector-to-target ratios and CDH17 expression levels, and was associated with lower cytokine release compared to a conventional TCE. LBL-054 TDC also mediated potent bystander killing of CDH17-negative tumor cells while sparing T cells. In an MC38/hCDH17 syngeneic mouse model, LBL-054 TDC demonstrated superior anti-tumor activity compared to TCE and ADC. In a 4-week dose-range finding (DRF) study in cynomolgus monkeys, LBL-054 TDC was well tolerated following repeated intravenous infusions.

• Abstract Title：LBL-054 TDC: A first-in-class CDH17 targeted T cell engager drug conjugate for the treatment of CDH17-positive gastrointestinal cancer

• Presentation Format：Poster

• Location：Section 17, Board #26

• Date & Time: April 21, 2026 (Tuesday), 2:00 PM – 5:00 PM PT

• Abstract Number：5857

LBL-061：A novel EGFR×PD-L1 targeted drug conjugate

LBL-061 is a novel EGFR×PD-L1-targeting ADC composed of a 2:2 format bispecific antibody conjugated via Leads Biolabs’ proprietary TOPiKinectics linker-payload platform. By merging the dual mechanisms of ADC-mediated tumor killing and immune activation, it synergistically enhances anti-tumor effects and is intended for solid tumors, including head and neck cancer, non-small cell lung cancer, and nasopharyngeal carcinoma.

Preclinical studies show that LBL-061 exhibits potent binding and cytotoxicity against a variety of tumor cells, while also demonstrating robust PD-1/PD-L1 blocking activity. In PBMC-tumor cell co-culture systems, it induced immunogenic cell death (ICD) in tumor cells and mediated a potent bystander effect on EGFR-negative tumor cells. In vivo, LBL-061 exhibited superior tumor growth inhibition in both syngeneic and xenograft mouse models. In a 6-week dose-range finding (DRF) study in cynomolgus monkeys, LBL-061 was well tolerated following repeated intravenous infusions (Q3W dosing), with a highest non-severely toxic dose (HNSTD) of 40 mg/kg.

• Abstract Title：LBL-061: A novel EGFR×PD-L1 targeted drug conjugate for the treatment of multiple solid tumors

• Presentation Format：Poster

• Location：Section 8, Board #20

• Date & Time: April 21, 2026 (Tuesday), 2:00 PM – 5:00 PM PT

• Abstract Number：5601

Executive Commentary

Dr. Hong Ling, Senior Vice President and Chief Scientific Officer of Leads Biolabs, stated, "The two programs selected for presentation at AACR demonstrate our core R&D strategy of IO 2.0 + ADC—by deeply synergizing and empowering our three core technology platforms, we integrate different mechanisms into a single molecule, fundamentally addressing the limitations of traditional therapies in terms of efficacy, safety, and resistance. We will continue to leverage our platform synergies, driven by mechanistic innovation and structural optimization, to efficiently advance innovative drug candidates with global competitiveness, bringing safer and more effective treatment options to patients."

About Leads Biolabs

Founded in 2012, Leads Biolabs is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies to address underserved medical needs in oncology, autoimmune, and other severe diseases both in China and globally.

We are a front-runner in next-generation immuno-oncology treatments with a differentiated pipeline of 14 innovative drug candidates, including seven clinical-stage drug candidates, of which four lead products are among the top-tier clinically advanced candidates globally.

We adopt a science-driven R&D approach and have successfully established comprehensive R&D capabilities spanning antibody discovery and engineering, in vivo and in vitro efficacy evaluation, as well as druggability assessment. We have also developed multiple proprietary technology platforms, including LeadsBody platform (a CD3 T-cell engager platform), X-body platform (a 4-1BB engager platform), TOPiKinectics (ADC platform), which serve as the cornerstone for our continued innovation and have been validated by the clinical outcomes of our bispecific antibody portfolios.

We have established integrated capabilities across early discovery, translational medicine, clinical development, CMC and business development. The innovative nature and competitive strengths of our drug candidates, coupled with our global perspectives, proactive strategy, and efficient clinical validation, have made us an attractive partner for leading industry players and investment institutions.

For more information, please visit https://en.leadsbiolabs.com/

Media Contact
Company Name: Leads Biolabs
Contact Person: Yizi
Email: Send Email
Country: China
Website: https://www.leadsbiolabs.com/